IL207989A0 - Orally disintegrating solid preparation - Google Patents

Orally disintegrating solid preparation

Info

Publication number
IL207989A0
IL207989A0 IL207989A IL20798910A IL207989A0 IL 207989 A0 IL207989 A0 IL 207989A0 IL 207989 A IL207989 A IL 207989A IL 20798910 A IL20798910 A IL 20798910A IL 207989 A0 IL207989 A0 IL 207989A0
Authority
IL
Israel
Prior art keywords
solid preparation
orally disintegrating
disintegrating solid
orally
preparation
Prior art date
Application number
IL207989A
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207989(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of IL207989A0 publication Critical patent/IL207989A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL207989A 2008-03-11 2010-09-05 Orally disintegrating solid preparation IL207989A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008061673 2008-03-11
JP2008334920 2008-12-26
PCT/JP2009/054983 WO2009113703A2 (en) 2008-03-11 2009-03-10 Orally-disintegrating solid preparation

Publications (1)

Publication Number Publication Date
IL207989A0 true IL207989A0 (en) 2010-12-30

Family

ID=40791576

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207989A IL207989A0 (en) 2008-03-11 2010-09-05 Orally disintegrating solid preparation

Country Status (26)

Country Link
US (2) US9241910B2 (enExample)
EP (1) EP2254556A2 (enExample)
JP (1) JP5604304B2 (enExample)
KR (1) KR20100129761A (enExample)
CN (2) CN104127368A (enExample)
AR (1) AR070863A1 (enExample)
AU (1) AU2009224254A1 (enExample)
BR (1) BRPI0909439A2 (enExample)
CA (1) CA2717947C (enExample)
CL (1) CL2009000557A1 (enExample)
CO (1) CO6321224A2 (enExample)
CR (1) CR11709A (enExample)
DO (1) DOP2010000273A (enExample)
EA (1) EA021792B1 (enExample)
EC (1) ECSP10010538A (enExample)
GE (1) GEP20135845B (enExample)
IL (1) IL207989A0 (enExample)
MA (1) MA32174B1 (enExample)
MX (1) MX2010009824A (enExample)
MY (1) MY173730A (enExample)
NZ (1) NZ588407A (enExample)
PE (2) PE20091620A1 (enExample)
TW (1) TWI441658B (enExample)
UY (1) UY31698A (enExample)
WO (1) WO2009113703A2 (enExample)
ZA (1) ZA201006679B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009224254A1 (en) 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
CA2729015A1 (en) * 2008-06-26 2009-12-30 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
EP3031451B1 (en) * 2009-01-26 2018-03-07 Shin-Etsu Chemical Co., Ltd Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
WO2012001705A2 (en) * 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
MX2013007588A (es) * 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.
CN102716097A (zh) * 2012-05-29 2012-10-10 浙江华海药业股份有限公司 控制口腔崩解片药物释放速率的方法
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
DK3257511T3 (en) * 2015-02-10 2019-01-21 Fujifilm Corp ORAL SOLUBLE TABLE AND METHOD OF PREPARING IT
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
BR112018017173A2 (pt) 2016-02-23 2019-01-02 Univ Colorado Regents composições e métodos para a produção e uso de formulações imunogênicas termoestáveis com compatibilidade aumentada de uso como vacinas contra um ou mais patógenos
EP3421032A4 (en) * 2016-02-23 2019-10-23 Nipro Corporation PARTICULARS OF A PHARMACEUTICAL COMPOSITION, ORAL DECOMPOSITION PREPARATION THEREOF AND METHOD FOR PRODUCING PARTICLES OF A PHARMACEUTICAL COMPOSITION
GB201607548D0 (en) * 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
CN110121342A (zh) * 2016-12-28 2019-08-13 富士胶片富山化学株式会社 医药组合物
PH12019500671B1 (en) * 2017-02-21 2024-02-02 Ea Pharma Co Ltd Granular preparation
JP7235193B2 (ja) * 2017-04-26 2023-03-08 大正製薬株式会社 固形組成物
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
CN111712235A (zh) 2018-01-16 2020-09-25 应用材料公司 金属氧化物包封的药物组合物及其制备方法
IL275875B2 (en) 2018-01-24 2024-10-01 Purdue Pharma Lp Sleep disorder treatment and prevention
TW201940171A (zh) * 2018-02-08 2019-10-16 景凱生物科技股份有限公司 類鴉片受體拮抗劑之固體劑型用之醫藥劑型
CA3127469A1 (en) 2019-01-31 2020-08-06 Purdue Pharma L.P. Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
EP4021423A4 (en) 2019-08-27 2023-11-08 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
CN112121067A (zh) * 2020-11-16 2020-12-25 深圳科兴药业有限公司 一种婴儿型双歧杆菌微胶囊及其制备方法
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
EP4340837A4 (en) 2021-05-21 2025-04-09 Purdue Pharma L.P. METHODS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
US12491165B2 (en) 2021-09-30 2025-12-09 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications
JPWO2023182332A1 (enExample) * 2022-03-22 2023-09-28
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN117860699A (zh) * 2024-01-07 2024-04-12 长沙晶易医药科技股份有限公司 一种细粒剂及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ATE481090T1 (de) 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
DE50113344D1 (de) * 2001-01-31 2008-01-17 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
IL159584A0 (en) * 2001-07-16 2004-06-01 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
BRPI0412697A (pt) 2003-07-17 2006-10-03 Reddys Lab Inc Dr composições farmacêuticas que apresentam um revestimento expansìvel
US20070259033A1 (en) 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
GB0323232D0 (en) * 2003-10-03 2003-11-05 Rolls Royce Plc Electrical machine
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
WO2005084649A1 (ja) 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited 安定なカプセル剤
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US9050249B2 (en) * 2004-04-30 2015-06-09 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
DE102004035936A1 (de) * 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
EP1839650A1 (en) 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Quick disintegration tablet and method of producing the same
GB0502479D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
FR2885526B1 (fr) 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
AU2006230974C1 (en) 2005-07-11 2012-02-02 Takeda Pharma A/S Benzimidazole formulation
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
EP1930030A1 (en) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Pulse preparation having improved disintegration properties in vivo
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
WO2007075980A2 (en) 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
KR100762847B1 (ko) 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1837016A3 (en) 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
US20090068263A1 (en) 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
CA2648495C (en) 2006-04-26 2016-07-05 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
EP2015731B1 (en) 2006-04-28 2013-11-06 Wockhardt Limited Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, acetaminophen and proton pump inhibitor
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
EP2040684B1 (en) 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
EP2068837A2 (en) 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
ES2547226T5 (es) 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
WO2008081891A1 (ja) * 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US9597293B2 (en) 2007-05-07 2017-03-21 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
AU2009224254A1 (en) 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
WO2010008569A1 (en) 2008-07-17 2010-01-21 Barr Laboratories, Inc. Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same
MX2013007588A (es) 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.

Also Published As

Publication number Publication date
MA32174B1 (fr) 2011-03-01
DOP2010000273A (es) 2010-09-30
CA2717947A1 (en) 2009-09-17
WO2009113703A3 (en) 2010-06-17
CA2717947C (en) 2020-07-07
PE20091620A1 (es) 2009-11-12
CN102026627A (zh) 2011-04-20
KR20100129761A (ko) 2010-12-09
TWI441658B (zh) 2014-06-21
US20150037423A1 (en) 2015-02-05
CN104127368A (zh) 2014-11-05
CN102026627B (zh) 2016-10-26
WO2009113703A2 (en) 2009-09-17
CR11709A (es) 2010-11-04
JP2011513204A (ja) 2011-04-28
UY31698A (es) 2009-11-10
AU2009224254A2 (en) 2010-11-18
CO6321224A2 (es) 2011-09-20
US9241910B2 (en) 2016-01-26
NZ588407A (en) 2012-07-27
EA201071054A1 (ru) 2011-04-29
CL2009000557A1 (es) 2010-10-01
GEP20135845B (en) 2013-06-10
PE20141034A1 (es) 2014-09-10
JP5604304B2 (ja) 2014-10-08
TW200944249A (en) 2009-11-01
MY173730A (en) 2020-02-18
EP2254556A2 (en) 2010-12-01
US20110091563A1 (en) 2011-04-21
ECSP10010538A (es) 2010-11-30
AR070863A1 (es) 2010-05-12
BRPI0909439A2 (pt) 2015-12-15
ZA201006679B (en) 2011-11-30
MX2010009824A (es) 2010-09-28
EA021792B1 (ru) 2015-09-30
AU2009224254A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
IL207989A0 (en) Orally disintegrating solid preparation
EP2196221A4 (en) QUICKLY CRUMPING SOLID PREPARATION
EP2251005A4 (en) TABLETS OFFERING ORALLY
EP2218443A4 (en) COMPRESSED ORALLY DISINTEGRATING
GB0917581D0 (en) Shredder
GB0913464D0 (en) Toilet
GB2467840B (en) Disease determination
IL207378A0 (en) Pharmaceutical solid state forms
ZA201108375B (en) Solid preparation
EP2262589A4 (en) CYCLONE
GB201003122D0 (en) Commode
EP2263661A4 (en) ORAL PREPARATION
EP2409688A4 (en) COMPRESSED ORAL DISCLAIMER
GB0906559D0 (en) Commode
EP2343059A4 (en) ORAL PREPARATION
TWI350155B (en) Towel
PL2428202T3 (pl) Kompozycje ulegające rozpadowi w jamie ustnej
GB0819293D0 (en) Radiofluorination
ZA201000791B (en) Stirrer Mill
GB0811288D0 (en) Shredder
GB2452486B (en) Towel
PL381690A1 (pl) Preparat biobójczy
GB0813809D0 (en) Le wedge
PL385644A1 (pl) Kruszarka ścianowa
GB2461512B (en) Can crusher